[Skip to Content]
[Skip to Content Landing]
Editorial
August 14, 2018

Low-Dose Combination Blood Pressure Pharmacotherapy to Improve Treatment Effectiveness, Safety, and Efficiency

Author Affiliations
  • 1Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 2Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 3Center for Healthful Behavior Change, Department of Population Health, New York University, New York, New York
  • 4Resolve to Save Lives, New York, New York
  • 5Kaiser Permanente South, San Francisco Medical Center South, San Francisco, California
JAMA. 2018;320(6):552-554. doi:10.1001/jama.2018.10649

In this issue of JAMA, Webster and colleagues1 report the results of the Triple Pill vs Usual Care Management for Patients with Mild-to-Moderate Hypertension (TRIUMPH) pragmatic randomized clinical trial that evaluated the efficacy of a low-dose combination pill containing 20 mg of telmisartan, 2.5 mg of amlodipine, and 12.5 mg of chlorthalidone compared with usual care among 700 adults with hypertension in Sri Lanka. The primary outcome was the proportion of patients whose blood pressure (BP) was controlled at 6 months, which was defined as a systolic/diastolic BP of less than 140/90 mm Hg or less than 130/80 mm Hg among patients with diabetes or chronic kidney disease at baseline or newly diagnosed (defined as an estimated glomerular filtration rate <60 mL/min/1.73 m2).

×